Notícias e Atividades da Journey Medical Corp

Journey Medical Corp pertence à Fortress Biotech.

Fortress Biotech é uma empresa listada sob o símbolo FBIO (US).

Fortress Biotech possui 4 subsidiárias incluindo Avenue Therapeutics, Checkpoint Therapeutics e Journey Medical Corp.

Eles estão dentro:

• Biotecnologia80%
• Farmacêutica20%

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da Journey Medical Corp

• Claude Maraoui, Director, President and Chief Executive Officer
• Michael Pearce, Director
• Justin Smith, Director

Recentes movimentos de executivos em Journey Medical Corp

• Ramsey Alloush antes General Counsel, foi promovido a Chief Operating Officer and General Counsel  (Notícia publicada em 2 de abril de 2025).
• Michael Pearce, ingressou na Companhia como Director  (Notícia publicada em 12 de julho de 2024).

Criar um alerta
para seguir os movimentos de executivos da Journey Medical Corp.

Fortress Biotech possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Eli Lilly (Estados Unidos) e Sanofi (França).

Popular M&A news in Farmacêutica

• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).
• Jazz Pharmaceuticals adquiriu Chimerix (publicado em 6 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Journey Medical Corp

• Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
• Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
• Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
• Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
• Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
• Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
• Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
• Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
• Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
• Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
• View more press releases Close

Redes sociais sobre Journey Medical Corp

• Journey Medical Corp na Wikipedia, Google News e Yahoo Finance
• Journey Medical Corp na LinkedIn, Twitter e YouTube